Sara A. Lewis

Sara A. Lewis

Auto-generated profile, based on publicly available information

Sara A. Lewis

Pediatric Movement Disorders Program, Barrow Neurological Institute, Phoenix Children’s Hospital, and Departments of Child Health, Neurology, Genetics, and Cellular & Molecular Medicine, University of Arizona College of Medicine, Phoenix, AZ 85004, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SJSheng Chih Jin
Sheng Chih Jin
SLSara A. Lewis
Sara A. Lewis
SBSomayeh Bakhtiari
Somayeh Bakhtiari
XZXue Zeng
Xue Zeng
MSMichael C. Sierant
Michael C. Sierant
MKMichael C. Kruer
Michael C. Kruer

9 April 2019 in Journal of Child Neurology
Verified
Journal Article
Open access
PDF file
AMAlastair H. MacLennan
Alastair H. MacLennan
SLSara Lewis
Sara Lewis
AMAndres Moreno-De-Luca
Andres Moreno-De-Luca
MFMichael Fahey
Michael Fahey
RLRichard J. Leventer
Richard J. Leventer
JGJozef Gecz
Jozef Gecz
High throughput sequencing is discovering many likely causative genetic variants in individuals with cerebral palsy. Some investigators have suggested that this changes the clinical diagnosis of cerebral palsy and that these individuals should be removed from this diagnostic category. Cerebral palsy is a neurodevelopmental disorder diagnosed on clinical signs, not etiology. All nonprogressive permanent disorders of movement and posture attributed to disturbances that occurred in the developing fetal and infant brain can be described as “cerebral palsy.” This definition of cerebral palsy should not be changed, whatever the cause. Reasons include stability, utility and accuracy of cerebral palsy registers, direct access to services, financial and social support specifically offered to families with cerebral palsy, and community understanding of the clinical diagnosis. Other neurodevelopmental disorders, for example, epilepsy, have not changed the diagnosis when genomic causes are found. The clinical diagnosis of cerebral palsy should remain, should prompt appropriate genetic studies and can subsequently be subclassified by etiology.

1 July 2017 in Neurobiology of Learning and Memory
Verified
Journal Article
Closed access
SLSara A. Lewis
Sara A. Lewis
DNDavid C. Negelspach
David C. Negelspach
SKSevag Kaladchibachi
Sevag Kaladchibachi
SCStephen L. Cowen
Stephen L. Cowen
FFFabian Fernandez
Fabian Fernandez

1 September 2023 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
SLSara A. Lewis
Sara A. Lewis
SBSomayeh Bakhtiari
Somayeh Bakhtiari
JFJacob Forstrom
Jacob Forstrom
ABAllan Bayat
Allan Bayat
FBFrédéric Bilan
Frédéric Bilan
MKMichael C. Kruer
Michael C. Kruer
AGAP1 is an Arf1 GTPase-activating protein that regulates endolysosomal trafficking. Damaging variants have been linked to cerebral palsy and autism. We report three new cases in which individuals had microdeletion variants in AGAP1. The affected individuals had intellectual disability (3/3), autism (3/3), dystonia with axial hypotonia (1/3), abnormalities of brain maturation (1/3), growth impairment (2/3) and facial dysmorphism (2/3). We investigated mechanisms potentially underlying AGAP1 variant-mediated neurodevelopmental impairments using the Drosophila ortholog CenG1a. We discovered reduced axon terminal size, increased neuronal endosome abundance and elevated autophagy compared to those in controls. Given potential incomplete penetrance, we assessed gene–environment interactions. We found basal elevation in the phosphorylation of the integrated stress-response protein eIF2α (or eIF2A) and inability to further increase eIF2α phosphorylation with subsequent cytotoxic stressors. CenG1a-mutant flies had increased lethality from exposure to environmental insults. We propose a model wherein disruption of AGAP1 function impairs endolysosomal trafficking, chronically activating the integrated stress response and leaving AGAP1-deficient cells susceptible to a variety of second-hit cytotoxic stressors. This model may have broader applicability beyond AGAP1 in instances where both genetic and environmental insults co-occur in individuals with neurodevelopmental disorders.

1 August 2021 in Neurology Genetics
Verified
Journal Article
Open access
SLSara A. Lewis
Sara A. Lewis
SBSomayeh Bakhtiari
Somayeh Bakhtiari
JHJennifer Heim
Jennifer Heim
PCPatricia Cornejo
Patricia Cornejo
JLJames Liu
James Liu
MKMichael C. Kruer
Michael C. Kruer
To determine whether mutations reported for ZDHHC15 can cause mixed neurodevelopmental disorders, we performed both functional studies on variant pathogenicity and ZDHHC15 function in animal models. We examined protein function of 4 identified variants in ZDHHC15 in a yeast complementation assay and locomotor defects of loss-of-function genotypes in a Drosophila model. Although we assessed multiple patient variants, only 1 (p.H158R) affected protein function. We report a patient with a diagnosis of hypotonic cerebral palsy, autism, epilepsy, and intellectual disability associated with this bona fide damaging X-linked variant. Features include tall forehead with mild brachycephaly, down-slanting palpebral fissures, large ears, long face, facial muscle hypotonia, high-arched palate with dental crowding, and arachnodactyly. The patient had mild diminished cerebral volume, with left-sided T2/FLAIR hyperintense periatrial ovoid lesion. We found that loss-of-function mutations in orthologs of this gene cause flight and coordinated movement defects in Drosophila. Our findings support a functional expansion of this gene to a role in motor dysfunction. Although ZDHHC15 mutations represent a rare cause of neurodevelopmental disability, candidate variants need to be carefully assessed before pathogenicity can be determined.

28 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LZLuz Jubierre Zapater
Luz Jubierre Zapater
SLSara A. Lewis
Sara A. Lewis
RGRodrigo Lopez Gutierrez
Rodrigo Lopez Gutierrez
MYMakiko Yamada
Makiko Yamada
ERElias Rodriguez-Fos
Elias Rodriguez-Fos
AKAlex Kentsis
Alex Kentsis
DNA transposable elements and transposase-derived genes are present in most living organisms, including vertebrates, but their function is largely unknown. PiggyBac Transposable Element Derived 5 (PGBD5) is an evolutionarily conserved vertebrate DNA transposase-derived gene with retained nuclease activity in human cells. Vertebrate brain development is known to be associated with prominent neuronal cell death and DNA breaks, but their causes and functions are not well understood. Here, we show that PGBD5 contributes to normal brain development in mice and humans, where its deficiency causes disorder of intellectual disability, movement, and seizures. In mice, Pgbd5 is required for the developmental induction of post-mitotic DNA breaks and recurrent somatic genome rearrangements. In the brain cortex, loss of Pgbd5 leads to aberrant differentiation and gene expression of distinct neuronal populations, including specific types of glutamatergic neurons, which explains the features of PGBD5 deficiency in humans. Thus, PGBD5 might be a transposase-derived enzyme required for brain development in mammals. One-Sentence Summary: PiggyBac Transposable Element Derived 5 (PGBD5) is required for brain development in humans and mice through genetic and epigenetic mechanisms.